Dr Reddy's Laboratories Ltd has signed an an exclusive 10-year agreement for the supply of the active ingredient AX200, a biological molecule in development.

Dr Reddy's Laboratories Ltd has signed an exclusive 10-year agreement for the supply of the active ingredient AX200, a biological molecule in development for the treatment of Stroke and other neurodegenerative disorders  with Sygnis Pharma AG. The agreement secures the supply of AX200 far beyond the clinical development and provides a solid basis for the envisaged marketing of the compound.

Sygnis has successfully completed a phase IIa clinical trial of AX200 in September that demonstrated safety and efficacy in patients with acute Stroke. In the second half of 2008, Sygnis plans to start a phase IIb efficacy trial in acute Stroke with AX200 supplied by the company. Stroke affects over five million patients worldwide every year and is the third leading cause of death, presenting a major socio-economic burden.